New cocktail aims to make liver cancer operable

NCT ID NCT06405061

First seen May 30, 2026 · Last updated Jun 13, 2026 · Updated 4 times

Summary

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and reduce the chance of cancer coming back. About 40 adults with a specific stage of liver cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Third Central Hospital of Tianjin

    Tianjin, Tianjin Municipality, China

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, 300308, China

  • Tianjin First Central Hospital

    Tianjin, Tianjin Municipality, China

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.